Avoiding Drug Resistance in HIV Reverse Transcriptase
Open accessThe DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.
Abstract
HIV reverse transcriptase (RT) is an enzyme that plays a major role in the replication cycle of HIV and has been a key target of anti-HIV drug development efforts. Because of the high genetic diversity of the virus, mutations in RT can impart resistance to various RT inhibitors. As the prevalence of drug resistance mutations is on the rise, it is necessary to design strategies that will lead to drugs less susceptible to resistance. Here we provide an in-depth review of HIV reverse transcriptase, current RT inhibitors, novel RT inhibitors, and mechanisms of drug resistance. We also present novel strategies that can be useful to overcome RT's ability to escape therapies through drug resistance. While resistance may not be completely avoidable, designing drugs based on the strategies and principles discussed in this review could decrease the prevalence of drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resistance to them mainly arises from the high error rate of HIV reverse transcriptase (RT) during replication. The key resistance mechanisms involve either excision, where a mutated RT removes an incorporated NRTI, or discrimination, where mutations alter the dNTP-binding pocket to selectively block NRTI-triphosphate incorporation (4, 40).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“NNRTIs inhibit HIV-1 reverse transcriptase (RT) by binding to a specific, non-catalytic hydrophobic pocket known as the non-nucleoside inhibitor binding pocket (NNIBP). This binding site is located approximately 10 Å from the polymerase active site. The interaction induces conformational changes in RT that disrupt its enzymatic function, thereby inhibiting viral DNA synthesis (40, 45).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Computational protein–ligand docking and virtual drug screening with the AutoDock suite
Forli, S., Huey, R., Pique, M. E., Sanner, M. F., Goodsell, D. S., & Olson, A. J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.051 · Cited by 2,811
Complete nucleotide sequence of the AIDS virus, HTLV-III
Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985) · Nature · doi:10.1038/313277a0 · Cited by 2,245
Computational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Research works printed but not linked: 8
- Vogt V., 1997, Retroviruses
- Telesnitsky A., 1997, Retroviruses
- Volberding P., 2002, AIDS Read., 12, 349
- D’Aquila R. T., 2003, Top HIV Med., 11, 92
- Kirby K. A., 2011, Cell. Mol. Biol., 57, 40
- Grobler, J. A.; Fillgrove, K.; Hazuda, D.; Huang, Q.; Lai, M. T.; Matthews, R. P.; Rudd, D. J.; Vargo, R. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW. In Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA , 2019; 481, http://www.croiconference.org/sessions/mk-8591-potency-and-pk-provide-high-inhibitory-quotients-low-doses-qd-and-qw (accessed 2020-07-13).
- Bekker, L-G.; Li, S. S.; Tolly, B.; Marzinke, M. A.; Mgodi, N.; Justman, J. E.; Swaminathan, S.; Adeyeye, A.; Farrior, J. H.; Sista, N. Hptn 076:Tmc278 ls safe, tolarable, and acceptable for HIV preexposure prophylaxis. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA , 2017.
- 2011, Janssen Products
Cited by
Items 101–117 of 117
BindingDB (2023) · UC San Diego · doi:10.7270/q2gh9nt5
BindingDB (2024) · UC San Diego · doi:10.7270/q20v8j4p
BindingDB Entry 50014324: Discovery of Novel Dihydrothiopyrano[4,3-
BindingDB (2022) · UC San Diego · doi:10.7270/q2057krw
BindingDB Entry 50015158: Development of Novel Dihydrofuro[3,4-
BindingDB (2023) · UC San Diego · doi:10.7270/q27948kb
Metadata
- Authors
- Cilento, M. E., Kirby, K. A., & Sarafianos, S. G.
- Affiliations
- Emory University (US)
- Corresponding author
- Sarafianos, Stefan G.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-01-28
- Volume
- 121
- Issue
- 6
- Pages
- 3271-3296
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- PMC
- PMC8149104
- OpenAlex
- W3125954347
- Cited by
- 106
- References
- 305
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 27 · 2023: 17 · 2022: 18 · 2021: 7
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01 AI121315, R37 AI076119, U54 AI150472)
- National Institute of General Medical Sciences (R01 GM118012, T32 GM008367)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- HIV reverse transcriptase, drug resistance, reverse transcriptase inhibitors, resistance mutations, HIV drug development, antiretroviral therapy
- MeSH terms
- Humans, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Virus Replication, Drug Design, Signal Transduction, HIV-1, HIV Infections, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.